{"id":391067,"date":"2016-09-12T00:00:00","date_gmt":"2016-09-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0003-2016-biopharma-rheumatoid-arthritis-current-treatment-physician-insights-eu5-2016\/"},"modified":"2026-04-29T11:43:25","modified_gmt":"2026-04-29T11:43:25","slug":"cutrim0003-2016-biopharma-rheumatoid-arthritis-current-treatment-physician-insights-eu5-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrim0003-2016-biopharma-rheumatoid-arthritis-current-treatment-physician-insights-eu5-2016\/","title":{"rendered":"Rheumatoid Arthritis | Current Treatment: Physician Insights | EU5 | 2016"},"content":{"rendered":"<p>Five TNF-\u03b1 inhibitors and four biologics with alternative mechanisms of action are currently approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain, United Kingdom). The TNF-\u03b1 inhibitors are the most widely prescribed biologics in RA patients refractory to conventional DMARDs owing to their efficacy, postmarketing safety data, and physicians\u2019 familiarity with them. However, the high-priced, branded TNF-\u03b1 inhibitors face a competitive threat from the recent launch of biosimilars, including biosimilar infliximab and biosimilar etanercept, which provide cost-effective alternatives. The\u00a0<i>Rheumatoid Arthritis Current Treatment (EU5)<\/i>\u00a0content provides in-depth analysis of rheumatologists\u2019 treatment and prescribing practices in the crowded RA market, including drivers of treatment selection, obstacles to biologics use, analysis of patient share, and anticipated changes in drug usage.<\/p>\n<ul>\n<\/ul>\n","protected":false},"template":"","class_list":["post-391067","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-current-treatment","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391067","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391067\/revisions"}],"predecessor-version":[{"id":394190,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391067\/revisions\/394190"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391067"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}